The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
Alzheimers Dement
; 17(5): 856-865, 2021 05.
Article
em En
| MEDLINE
| ID: mdl-33928754
ABSTRACT
INTRODUCTION:
The Clinician's Interview-Based Impression of Change Plus caregiver input (CIBIC-Plus) has been widely used in dementia drug trials to evaluate cognition, behavior, and function. New trials of symptomatic drugs forecast renewed interest in this measure.METHODS:
To test its clinical meaningfulness, we examined how CIBIC-Plus performed in two cholinesterase inhibitor trials compared to goal attainment scaling Scale (GAS) scores, a patient-reported outcome measure.RESULTS:
Net goal attainment was seen for all but one GAS domains in subjects who improved on the CIBIC-Plus. Subjects who improved initially on CIBIC-Plus scores were likely to remain improved across all other outcomes for each trial's duration, except for Disability Assessment for Dementia scores.DISCUSSION:
The initial response to treatment, as assessed by CIBIC-Plus, remained stable for most outcome measures. Even small CIBIC-Plus improvement changes are associated with clinically meaningful change as assessed by GAS. Other tests detect decline better than improvement.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Índice de Gravidade de Doença
/
Inibidores da Colinesterase
/
Cuidadores
/
Nootrópicos
/
Doença de Alzheimer
/
Medidas de Resultados Relatados pelo Paciente
/
Donepezila
/
Galantamina
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Qualitative_research
Aspecto:
Patient_preference
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Alzheimers Dement
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Canadá